Eiger Biopharmaceutica Price To Book vs. Return On Equity

EIGRDelisted Stock  USD 0.74  0.03  3.90%   
Based on the key profitability measurements obtained from Eiger Biopharmaceutica's financial statements, Eiger Biopharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Eiger Biopharmaceutica's ability to earn profits and add value for shareholders.
For Eiger Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eiger Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eiger Biopharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eiger Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eiger Biopharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Please note, there is a significant difference between Eiger Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eiger Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eiger Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Eiger Biopharmaceuticals Return On Equity vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Eiger Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Eiger Biopharmaceutica value to that of its competitors to determine the firm's financial worth.
Eiger Biopharmaceuticals is rated below average in price to book category among its peers. It is rated below average in return on equity category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Eiger Biopharmaceutica by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Eiger Return On Equity vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Eiger Biopharmaceutica

P/B

 = 

MV Per Share

BV Per Share

 = 
0.87 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Eiger Biopharmaceutica

Return On Equity

 = 

Net Income

Total Equity

 = 
-2.26
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Eiger Return On Equity Comparison

Eiger Biopharmaceutica is currently under evaluation in return on equity category among its peers.

Eiger Biopharmaceutica Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Eiger Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eiger Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Eiger Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Eiger Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Eiger Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.

Eiger Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Eiger Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eiger Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eiger Biopharmaceutica's important profitability drivers and their relationship over time.

Use Eiger Biopharmaceutica in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

Eiger Biopharmaceutica Pair Trading

Eiger Biopharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Eiger Biopharmaceutica position

In addition to having Eiger Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Picks Thematic Idea Now

Macroaxis Picks
Macroaxis Picks Theme
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in Eiger Stock

If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Share Portfolio
Track or share privately all of your investments from the convenience of any device